An ANI Pharmaceuticals executive sold 4,772 shares worth $357,471 on March 11, 2026, representing routine portfolio trimming rather than a bearish signal. The company reported record 2025 revenue of $883.4 million (up 43.8% YoY) driven by strong rare disease segment growth, with management guiding for over $1 billion in 2026 revenue.

ANI Pharmaceuticals announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, prior to market open. The company expects full year 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above guidance ranges. A conference call will be hosted by CEO Nikhil Lalwani and other executives to discuss the results.

Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.

CG Oncology announced that its leadership will participate in two upcoming investor conferences in September 2025, presenting at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference.

Cg Oncology reported a wider net loss in Q2 2025, with no revenue and increased R&D expenses. The company continues developing a gene therapy for bladder cancer and plans to submit a Biologics License Application in Q4 2025.

ANI Pharmaceuticals reported record quarterly net revenues of $197.1 million, a 43.4% year-over-year growth. The company's Rare Disease business generated $69.0 million in quarterly net revenues and presented preclinical data on the use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis mouse model.

ANI Pharmaceuticals reported strong Q4 results, with adjusted EPS and sales beating estimates. The company raised its 2025 guidance for revenue and adjusted EPS, driven by growth in its Cortrophin Gel, generics, and branded products.

ANI Pharmaceuticals, Inc. announced that it will release its third quarter 2024 financial results on November 8, 2024, and host a conference call to discuss the results.

Avadel Pharmaceuticals received FDA approval to expand the label of its narcolepsy drug Lumryz to include treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older. This expands the drug's indication to the pediatric population and is expected to boost sales.

Alnylam Pharmaceuticals has submitted a regulatory filing in the EU for its investigational drug vutrisiran to treat ATTR amyloidosis with cardiomyopathy. The filing is supported by positive results from a late-stage study, and if approved, the drug has the potential to become the new standard of care for ATTR-CM treatment.

Biohaven's pipeline candidate, troriluzole, met the primary endpoint in a pivotal study for the treatment of spinocerebellar ataxia, a rare neurological disease. The study showed a 50-70% delay in disease progression compared to untreated patients.

ANI Pharmaceuticals has completed the acquisition of Alimera Sciences, strengthening its Rare Disease segment and expanding its ophthalmology portfolio. The transaction is expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and be substantially accretive thereafter.